Chinese Peptide

Chinese Peptide, established in 2001, operates as a premier Contract Development and Manufacturing Organization (CDMO) specializing in synthetic peptide production. The company serves as a critical partner for biotechnology and pharmaceutical firms, facilitating the transition of therapeutics and diagnostics from early-stage drug discovery through clinical trials to full-scale commercial manufacturing. By focusing on high-quality synthetic peptide synthesis, Chinese Peptide supports global healthcare innovation and regulatory compliance.

The organization maintains the world's largest Good Manufacturing Practice (GMP) peptide facility, which has successfully passed multiple FDA inspections and rigorous audits by international pharmaceutical entities. This infrastructure allows Chinese Peptide to provide comprehensive regulatory support and industrial-scale API preparation. Their technical capabilities ensure that complex peptide sequences are manufactured to meet stringent quality standards, enabling clients to navigate the complexities of drug development with precision and reliability.

With a workforce of 500-1,000 employees, Chinese Peptide leverages deep expertise in engineering, science, and operations to maintain its market position in the Asia-Pacific region. The company’s commitment to excellence is reflected in its robust operational framework and specialized technical teams. Meet Chinese Peptide's team to learn more about the professionals driving these advancements in peptide manufacturing. Through its strategic focus on B2B pharmaceutical services, the company continues to expand its influence in the global healthcare sector, providing essential resources for life-changing medical breakthroughs.